These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34050972)

  • 1. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Al-Sawaf O; Gentile B; Devine J; Zhang C; Sail K; Tandon M; Fink AM; Kutsch N; Wendtner CM; Eichhorst B; Hallek M; Fischer K
    Am J Hematol; 2021 Sep; 96(9):1112-1119. PubMed ID: 34050972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
    Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    Nat Commun; 2023 Apr; 14(1):2147. PubMed ID: 37072421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
    Al-Sawaf O; Zhang C; Lu T; Liao MZ; Panchal A; Robrecht S; Ching T; Tandon M; Fink AM; Tausch E; Schneider C; Ritgen M; Böttcher S; Kreuzer KA; Chyla B; Miles D; Wendtner CM; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    J Clin Oncol; 2021 Dec; 39(36):4049-4060. PubMed ID: 34709929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
    Al-Sawaf O; Robrecht S; Zhang C; Olivieri S; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Sivchev L; Niemann CU; Schwarer A; Loscertales J; Weinkove R; Strumberg D; Kilfoyle A; Manzoor BS; Jawaid D; Emechebe N; Devine J; Boyer M; Runkel ED; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    Blood; 2024 Oct; 144(18):1924-1935. PubMed ID: 39082668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
    Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
    Sheng Z; Song S; Yu M; Zhu H; Gao A; Gao W; Ran X; Huo D
    Leuk Lymphoma; 2020 Dec; 61(14):3432-3439. PubMed ID: 32862749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
    Blair HA
    Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
    Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
    N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
    Cho SK; Manzoor BS; Sail KR; Parisé H; Ravelo A; Shapouri S; Kapustyan T; Sharmokh S; Virabhak S; Davids MS; Johnson S
    Pharmacoeconomics; 2020 Sep; 38(9):941-951. PubMed ID: 32383129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Cochrane T; Enrico A; Gomez-Almaguer D; Hadjiev E; Lech-Maranda E; Masszi T; Nikitin E; Robak T; Weinkove R; Wu SJ; Sail KR; Pesko J; Pai M; Komlosi V; Anderson MA
    Leuk Lymphoma; 2022 Feb; 63(2):304-314. PubMed ID: 34632935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
    Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
    Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
    Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
    Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F
    Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Salvaris R; Opat S
    Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
    Blood; 2024 Jul; 144(3):341. PubMed ID: 39023875
    [No Abstract]   [Full Text] [Related]  

  • 20. Frontline treatment in CLL: the case for time-limited treatment.
    Lévy V; Delmer A; Cymbalista F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.